XYone Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of XYA02(AT2021), a Novel Antibody Drug Conjugate targeting MUC1-C

Phase 1XYA02Positive

AI Analysis

Summary

XYone Therapeutics announced the first patient dosed in a Phase 1b/2 clinical trial of XYA02 (AT2021), a novel antibody-drug conjugate targeting MUC1-C.

Clinical Trial Data

Phase

1b/2

Importance:5/10

Sentiment:

0.60

antibody-drug conjugatefirst-in-humanclinical trialoncology

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on September 29, 2026 2:03 PM

Read Original